EVIDENCE VS HYPE · CREATINE & BONE HEALTH
The hype: Creatine builds stronger muscles, so it must also strengthen your skeleton and help prevent osteoporosis.
Bone health is a sensible concern, especially around menopause and later life. Stronger muscles could help someone stay active, and exercise can place useful loads on bones. Yet this chain of reasoning does not establish that creatine itself increases bone density or prevents fractures. We investigated the direct human evidence for that extra step.
The short answer
Creatine is not an established treatment for osteoporosis. Trials have not consistently shown an additional bone-mineral-density benefit, including a substantial two-year study alongside exercise. Some findings on bone geometry are interesting, but they do not demonstrate fewer fractures. Considering creatine for strength training is a different decision from using it to treat fragile bones.
Why people believe it
Muscles and bones work together. A supplement that helps training might indirectly increase the load placed on bone, and experimental mechanisms can suggest effects on bone cells. That makes further research reasonable. It does not make a clinical recommendation inevitable: a plausible biological pathway must still produce a useful outcome in people.
The claim here is that taking creatine improves bone health beyond the same exercise or usual care without it. If both trial groups train and both benefit, that cannot be credited to the supplement. Likewise, increased lean mass is not a bone measurement. Keeping these distinctions clear prevents genuine muscle findings from becoming unsupported osteoporosis marketing.
What the evidence says
A two-year trial did not improve the main bone outcome
Chilibeck and colleagues randomised 237 postmenopausal women, with a mean age of 59, to creatine or placebo during a two-year exercise programme. The programme included resistance training three times weekly and walking six times weekly. Creatine was given at 0.14 g per kilogram of body weight daily.
The primary outcome, femoral-neck bone mineral density, did not improve with creatine compared with placebo. There was no additional density benefit at the total hip or lumbar spine. This matters because the trial was considerably longer than many supplement studies and directly compared groups undertaking exercise.
Some secondary measurements of hip-bone geometry were more favourable with creatine. These describe structural characteristics that could influence strength, but are not the same as demonstrating fracture prevention. A positive secondary signal cannot turn a negative primary density result into proof that the supplement treats osteoporosis. Read the two-year randomised trial.
The broader trial evidence has not established a density benefit
A 2026 systematic review specifically examined creatine in postmenopausal women. Seven trials randomised 608 participants, with intervention periods of 12–104 weeks. It reported small advantages in some muscle outcomes, but did not establish a consistent improvement in bone mineral density. The review was not prospectively registered, a limitation when assessing how analytical decisions were made.
This is an important separation: an intervention can be useful for a muscle-related goal and remain unproven for bone density. The evidence also applies mainly to the populations studied, rather than every age group or everyone with an osteoporosis diagnosis. Read the 2026 postmenopausal-women review.
An earlier meta-analysis of creatine during resistance training in older adults reached a similar conclusion about the absence of a greater density benefit. New reviews include some older trials, so apparent agreement should not be mistaken for independent replication by completely new participants. Nevertheless, the general density result has not been reversed by the longer trial. Read the 2018 bone-density meta-analysis.
The catch: bone density, structure and fractures are different
Bone mineral density, usually assessed using a DXA scan, helps clinicians estimate fracture risk. It is useful but does not capture every feature of bone strength. Geometry measurements may add information about shape and resistance to loading. Neither can automatically tell us how many people will avoid a hip or spinal fracture after supplementation.
Fractures depend on bone strength, falls, balance, medicines, vision and other factors. A trial measuring muscle strength or walking speed may support a functional question without answering the fracture question. To substantiate a prevention claim, we need appropriate clinical outcomes, adequate follow-up and enough participants to detect meaningful differences.
Two years is relatively long for a supplement trial, but remains short in the context of lifelong skeletal health. Smaller studies, differing doses and variable exercise programmes leave uncertainties about specific subgroups. Those limitations justify further investigation; they do not justify presenting an unobserved benefit as likely or guaranteed.
Funding and researcher interests also matter in supplement research. We prioritised randomised comparisons and the primary outcomes over enthusiastic interpretations. Where only a bibliographic record or abstract was accessible, we did not infer unreported funding arrangements, detailed subgroup effects or adherence results. No claim of a complete independent reanalysis of trial data is being made.
What this means for you
If bone health is your main concern, seek an assessment of your actual risk rather than choosing a supplement on the strength of a muscle-building reputation. NHS guidance explains that osteoporosis treatment depends on fracture risk and may include prescribed medicines, with calcium and vitamin D where appropriate. Creatine should not replace indicated treatment or delay investigation after a fragility fracture.
Weight-bearing activity and resistance exercise can be part of bone-health care, but the programme needs to suit you. If you have osteoporosis, a previous fracture or significant pain, ask a qualified clinician or physiotherapist about safe progression. “Lift heavier” is not a complete plan for every person.
Someone considering plain creatine for a separate strength-training goal may still reasonably discuss it with a professional. They should not expect it to correct low bone density, and should not increase the dose in an attempt to force a bone effect. No osteoporosis-specific creatine regimen is established by these studies.
Explore all Creatine investigations → See also our investigation of creatine and strength in older adults.
Research & Sources
- Chilibeck et al. (2023): two-year postmenopausal bone-health randomised trial.
- Naddafha et al. (2026): postmenopausal-women systematic review and meta-analysis.
- Forbes et al. (2018): bone-density meta-analysis in older adults.
- NHS: osteoporosis treatment.
- NHS: osteoporosis prevention.
Evidence reviewed: October 2026. Educational information, not individual medical advice. No commercial product was tested or endorsed. Buying guidance and any disclosed affiliate recommendations remain separate from this verdict.